Donor immune cell treatment for relapsed or stubborn AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that is relapsed or has not responded to induction chemotherapy
- You are 1 to 24.99 years old
- If you could become pregnant, you must have a negative pregnancy test and use effective birth control during the study and for 6 months after the last chemo/NK cell dose
- You must not have uncontrolled infections, and your heart, liver, and kidney tests must meet the study limits
- You need to have recovered from prior treatment side effects to mild levels (no worse than “Grade 2”), unless the study doctor approves otherwise
- You must be able to sign consent (with a parent/guardian if needed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a lab-made immune-cell treatment (NK cells) for children with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It aims to help the immune system attack leukemia cells in the bone marrow, especially when standard treatments have not worked.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial tests if giving special immune cells from a donor can clear leftover leukemia cells in patients who are in remission but still have traces of cancer after chemotherapy.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.